Jessi Jordan
Acute Care · Columbia, SCNPI 1841904141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.7% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.5% — the pattern of someone who eats at a lot of different presentations.
Across 101 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$350
- AstraZeneca$232
- Daiichi Sankyo Inc.$129
- Bristol Myers Squibb$120
- Johnson & Johnson$115
- Genentech USA, Inc.$110
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,09793%
- Education$1657%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 15 | $350 |
| AstraZeneca(2 entities) | 9 | $232 |
| Daiichi Sankyo Inc. | 6 | $129 |
| Bristol Myers Squibb | 6 | $120 |
| Johnson & Johnson | 5 | $115 |
| Genentech USA, Inc. | 6 | $110 |
| Astellas Pharma US Inc | 2 | $107 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| Regeneron Healthcare Solutions, Inc. | 4 | $92 |
| AbbVie | 4 | $89 |
| Incyte Corporation | 4 | $82 |
| Pfizer | 3 | $51 |
| Merck | 2 | $50 |
| Geron Corporation | 2 | $45 |
| Bayer | 2 | $40 |
| EMD Serono, Inc. | 2 | $33 |
| Legend Biotech USA Inc. | 1 | $33 |
| Array Biopharma Inc | 2 | $32 |
| Janssen Scientific Affairs, LLC | 1 | $32 |
| Iovance Biotherapeutics, Inc. | 1 | $29 |
| Syndax Pharmaceuticals, Inc. | 1 | $28 |
| Eisai Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| AVEO Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Beigene USA, Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Karyopharm Therapeutics Inc. | 1 | $20 |
| Pharmaessentia USA Corporation | 1 | $20 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $17 |
| Tempus AI, Inc | 1 | $17 |
How this compares
$2,262 in reported general payments places this provider in the 75th percentile of 339 acute care providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 13 | $291 |
| Ondansetron OdtOndansetron | 13 | $102 |
| Tramadol Hcl | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Other acute care in Columbia
- Michael GajewskiColumbia$62K
- Micheal BungerColumbia$15K
- Robin TrauflerColumbia$12K
- Linda VanduysColumbia$7K
- Aziz PetiwalaColumbia$7K
- Christina AdkinsColumbia$6K
- Brandon PalmerColumbia$6K
- Sarah Ford-SightlerColumbia$6K
- Jessica WheelerColumbia$6K
- Stacy SandersColumbia$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.